Bicara Financial Statements From 2010 to 2026

BCAX Stock   16.72  0.03  0.18%   
Bicara Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Bicara Therapeutics' valuation are provided below:
Market Capitalization
917.6 M
Earnings Share
5.38
We have found one hundred one available fundamental signals for Bicara Therapeutics Common, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Bicara Therapeutics Common prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 971.2 M in 2026
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 225.8 K, Net Interest Income of 17.6 M or Interest Income of 17.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Bicara Stock
Check out the analysis of Bicara Therapeutics Correlation against competitors.

Bicara Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets687.3 M654.6 M131.3 M
Slightly volatile
Other Current Liabilities11.5 M11.6 M17.1 M
Slightly volatile
Total Current Liabilities15.2 M16.2 M22.1 M
Slightly volatile
Property Plant And Equipment Net841.9 K971.8 K690.7 K
Slightly volatile
Accounts Payable3.4 M4.1 M4.8 M
Slightly volatile
Cash591.3 M563.2 M113.5 M
Slightly volatile
Non Current Assets Total80.5 M76.7 M14.7 M
Slightly volatile
Non Currrent Assets OtherM7.6 M2.3 M
Slightly volatile
Cash And Short Term Investments591.3 M563.2 M113.5 M
Slightly volatile
Common Stock Shares Outstanding57.9 M62.6 M52.9 M
Slightly volatile
Liabilities And Stockholders Equity687.3 M654.6 M131.3 M
Slightly volatile
Non Current Liabilities Total71.6 M68.2 M11.8 M
Slightly volatile
Other Current Assets15.5 M14.7 M3.2 M
Slightly volatile
Other Stockholder Equity860.8 M819.8 M142.8 M
Slightly volatile
Total Liabilities93.4 M88.9 M34.5 M
Slightly volatile
Property Plant And Equipment Gross841.9 K971.8 K690.7 K
Slightly volatile
Total Current Assets606.8 M577.9 M116.7 M
Slightly volatile
Capital StockK8.1 K2.8 K
Slightly volatile
Non Current Liabilities Other14.5 K15.3 K68.8 K
Slightly volatile
Common StockK8.1 K2.8 K
Slightly volatile
Short and Long Term Debt Total767.2 K848.7 K679.5 K
Slightly volatile
Short Term Debt490.6 K698 K340.3 K
Slightly volatile

Bicara Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision225.8 K215.1 K38 K
Slightly volatile
Interest Income17.6 M16.8 MM
Slightly volatile
Depreciation And Amortization67.6 K64.4 K19.8 K
Slightly volatile
Selling General Administrative12.6 M21.6 M8.5 M
Slightly volatile
Other Operating Expenses58.6 M94.7 M45 M
Slightly volatile
Research Development46 M73.2 M36.5 M
Slightly volatile
Cost Of Revenue67.6 K64.4 K19.8 K
Slightly volatile
Total Operating Expenses58.6 M94.7 M45 M
Slightly volatile
Reconciled Depreciation67.6 K64.4 K19.8 K
Slightly volatile
Income Tax Expense225.8 K215.1 K38 K
Slightly volatile

Bicara Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.9 M8.5 M2.2 M
Slightly volatile
Begin Period Cash Flow278.3 M265 M49.4 M
Slightly volatile
Other Cashflows From Financing Activities1.4 M1.4 M40.5 M
Pretty Stable
Depreciation67.6 K64.4 K19.8 K
Slightly volatile
Capital Expenditures60.7 K63.9 K192.8 K
Very volatile
Issuance Of Capital Stock233.3 M382.3 M95.9 M
Slightly volatile
Total Cash From Financing Activities234 M384.1 M96.3 M
Slightly volatile
End Period Cash Flow591.3 M563.2 M113.5 M
Slightly volatile
Other Cashflows From Investing Activities49.6 K55.8 K60.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation1.391.4616.7388
Slightly volatile
Cash Per Share8.58.11.8291
Slightly volatile
Income Quality0.750.990.8668
Slightly volatile
Net Debt To EBITDA3.155.351.2727
Slightly volatile
Current Ratio26.425.145.7355
Slightly volatile
Debt To Equity0.00250.00170.0028
Slightly volatile
Capex Per Share0.00140.00150.0038
Very volatile
Interest Debt Per Share0.00760.01220.0044
Slightly volatile
Debt To Assets0.00230.00150.0026
Slightly volatile
Ebt Per Ebit1.140.951.0165
Pretty Stable
Total Debt To Capitalization0.00250.00170.0028
Slightly volatile
Debt Equity Ratio0.00250.00170.0028
Slightly volatile
Quick Ratio26.425.145.7355
Slightly volatile
Net Income Per E B T0.80.90.9825
Slightly volatile
Cash Ratio25.7224.55.587
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0207
Slightly volatile
Debt Ratio0.00230.00150.0026
Slightly volatile

Bicara Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.2 B1.1 B1.2 B
Slightly volatile
Enterprise Value971.2 M528 M1.1 B
Slightly volatile

Bicara Fundamental Market Drivers

About Bicara Therapeutics Financial Statements

Bicara Therapeutics investors use historical fundamental indicators, such as Bicara Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bicara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue64.4 K67.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bicara Stock Analysis

When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.